期刊文献+

经皮肾动脉去交感神经消融术治疗顽固性高血压疗效观察 被引量:2

Evaluate the effects of renal sympathetic denervation on patients with resistant hypertension
下载PDF
导出
摘要 目的观察肾动脉去交感神经消融术治疗顽固性高血压患者术后6个月内的血压变化及用药情况,观察该手术对血压的影响。方法对比观察15名于本院行肾动脉去交感神经消融术患者术前及术后1、3、6个月血压变化,观察术后血压达标率;对比观察术前术后药物使用种类及并发症。结果患者术前及术后1、3、6个月收缩压分别为(164±14)mm Hg、(138±11)mm Hg、(138±8)mm Hg、(135±7)mm Hg;舒张压分别(98±10)mm Hg、(84±9)mm Hg、(83±7)mm Hg、(81±8)mm Hg;收缩压和舒张压术前与术后比较,差异均有统计学意义(P<0.05);术后1、3、6个月血压达标率分别为66.7%、80.0%、86.7%。患者服药种类由术前的(3.6±0.9)种降至术后的(2.4±0.8)种(P<0.05);所有患者均未发现近期及远期并发症。结论肾动脉去交感神经消融术治疗顽固性高血压有效、安全;术后降压效应有一定的时间延续性。 Objective To observe the blood pressure and drug using whithin 6 months of renal sympathetic denervation(RDN) on patients with resistant hypertension. Methods 15 patients with resistant hypertension after renal sympathetic denervation were observed.The the blood pressure(BP), ratio of BP up to the standard,types of drug using and complications were observed before RDN and after RDN in 1, 3, 6months. Results The Systolic diastolic blood pressure before RDN and after RDN in 1, 3, 6months were (164±14)mmHg, (138±11)mmHg, (138±8) mmHg,(135±7)mm Hg(P 〈 0.05), the diastolic blood pressure before RDN and after RDN in 1, 3, 6months were (98±10)mm Hg, (84±9)mm Hg, (83±7)mm Hg, (81±8)mm Hg(P〈0.05).The ratio of BP up to the standard were 66.7%, 80.0%, 86.7%(P〈0.05). The types of drug using were (3.6±0.9) kinds before RDN and decreased to (2.4±0.8) kinds after RDN(P〈0.05).All patients had no complications. Conclusion RDN can be safety and effectively used in patients with resistant hypertension and the effects have Time continuity.
出处 《中国医药科学》 2014年第23期34-36,共3页 China Medicine And Pharmacy
关键词 肾动脉去交感神经消融术 顽固性高血压 Renal sympathetic denervation(RDN) Resistant hypertension
  • 相关文献

参考文献13

  • 1Calhoun DA,Jones D,Textor S,et al.Resistant hypertension:diagnosis,evaluation,and treatment[J].Circulation,2008,51:1403-1419.
  • 2Grasi G.Asesment of sympathetic cardiovascular drive in human hypertension:achievements and perspectives[J].Hypertension,2009,54(4):690-697.
  • 3Atherton DS,Deep NL,Mendelsohn FO.Micro-anatomy of the renal sympathetic nervous system A human postmortem histologic study[J].Clin Anat,2012,25:628-633.
  • 4Symplicity HTN-1 Investigators.Catheter-based renal sympathetic denervation for resistant hypertension:durability of blood pressure reduction out to 24months[J].Hypertension,2011,57:911-917.
  • 5Symplicity HTN-2 Investigators,Esler MD,Krum H,et al.Renalsympathetic denervation in patients with treatment-resistant hypertension(The Symplicity HTN-2Trial):a randomized controlled trial[J].The Lancet,2010,376:1903-1909.
  • 6Persu A,Jin Y,Azizi M,et al.Blood pressure changes after renal denervation at 10 European expert centers[J].J Hum Hypertens,2014,28(3):150-156.
  • 7Gosain P,Garimella PS,Hart PD,et al.Renal sympathetic denervation for treatment of resistant hypertension a systematic review[J].J Clin Hypertens,2013,15:75-84.
  • 8Mahfoud F,Schlaich M,Kindermann I,et al.Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertensiona pilot study[J].Circulation,2011,123:1940-1946.
  • 9靳文英,乔正国,郑春华,李素芳,陈红.蛋白激酶C结合蛋白1参与心力衰竭小鼠心脏去甲肾上腺素转运蛋白的表达下调[J].中华心血管病杂志,2014,42(3):219-224. 被引量:4
  • 10周超飞(综述),任艺虹(审校).经皮导管射频消融肾交感神经治疗顽固性高血压的研究进展[J].中国医师杂志,2012,14(2):274-276. 被引量:4

二级参考文献39

  • 1刘力生.中国高血压防治指南2010[J].中国医学前沿杂志(电子版),2011,3(5):42-93. 被引量:1216
  • 2Metra M, Davison B, Bettari L, et aI. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail, 2012, 5 :54-62.
  • 3Ronco C, Cicoira M, McCullough PA. Cardiorenal syndrome type I: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure.J Am Coli Cardiol, 2012, 60:1031-1042.
  • 4Dickstein K, Cohen-Solal A, Filippatos G, et aI. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collahoration with the Heart Failure Association of the ESC (HF A) and endorsed by the European Society of Intensive Care Medicine (ESICM). EurJ Heart Fail, 2008, 10 :933-989.
  • 5Weber KT. Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain.J Am Coli Cardiol, 2004,44:1308-1310.
  • 6Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/ AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundationl American Heart Association Task Force on Practice Guidelines Developed in Collahoration With the International Society for Heart and Lung Transplantation.J Am Coli Cardiol, 2009, 53: e1-e90.
  • 7Costanzo MR, Saltzberg M, 0' SullivanJ, et al. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance.J Am Coli Cardiol, 2005, 46 :2047-2051.
  • 8Giglioli C, Landi D, Cecchi E, et al. Effects of ULTRAfiltration vs. DlureticS on clinical, biohumoral and haemodynamic variables in patients with deCOmpensated heart failure: the ULTRADISCO study. EurJ Heart Fail, 2011, 13 :337-346.
  • 9Costanzo MR, Saltzberg MT,Jessup M, et al. Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD.J Card Fail, 2010,16:277-284.
  • 10Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. N EnglJ Med, 2012, 367 :2296-2304.

共引文献15

同被引文献23

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部